Effect of aripiprazole on cognition in the treatment of patients with schizophrenia

Pharmacopsychiatry

Volumn 43, Issue 2, 2010, Pages 50-57

  Riedel, M ^a   Spellmann, I ^a   Schennach Wolff, R ^a   Musil, R ^a   Dehning, S ^a   Cerovecki, A ^a   Opgen Rhein, M ^a   Matz, J ^a   Seemuller F ^a   Obermeier, M ^a   Severus, E ^a   Engel, R R ^a   Muller N ^a   Moller H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; DIAZEPAM; LORAZEPAM; PROPANOL; ZOPICLONE;

ADULT; AKATHISIA; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; REACTION TIME; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VERBAL MEMORY; VISUAL MEMORY; WEIGHT GAIN; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; HUMANS; INPATIENTS; MEMORY; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; REACTION TIME; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949891795     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1239539     Document Type: Article

References (44)

1. Akdede BB, nil Yagcioglu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006 67 1912-1919
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association, Washington DC 1994
3. Andersen B. Regression toward the mean. In: Methodological errors in medical research. Blackwell Scientific Publications, London 1990 pp 98-108
4. Beasley CM, Jr, Tollefson G, Tran P, etal. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996 14 111-123
5. Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002 159 1018-1028
6. Bilder RM, Reiter G, Bates J et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol 2006 28 270-282
7. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 302 381-389
8. Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 1998 25 175-178
9. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009 166 675-682
10. Dossenbach M, rango-Davila C, Silva IH et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005 66 1021-1030
11. Fujii DE, Wylie AM, Nathan JH. Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res 2004 69 67-73
12. Gold JM, Carpenter C, Randolph C et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997 54 159-165
13. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007 64 1115-1122
14. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996 153 321-330
15. Gutbrod K, Cohen R, Mager B et al. Coding and recall of categorized material in aphasics. J Clin Exp Neuropsychol 1989 11 821-841
16. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology National Institute of Mental Health, Rockville, MD revised 1976
17. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003 64 (Suppl 19) 33-39
18. Hawkins KA. Memory deficits in patients with schizophrenia: preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings. J Psychiatry Neurosci 1999 24 341-347
19. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998 12 426-445
20. Ichikawa J, Dai J, O IA et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002 26 325-339
21. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007 64 633-647
22. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1998 23 99-110
23. Keefe RS, Roitman SE, Harvey PD et al. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 1995 17 25-33
24. Keefe RS, Silva SG, Perkins DO et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999 25 201-222
25. Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 164 1061-1071
26. Kern RS, Green MF, Cornblatt BA et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 187 312-320
27. Lindenmayer JP, Khan A, Iskander A et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007 68 368-379
28. Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987 334 1-100
29. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000 295 853-861
30. Milev P, Ho BC, Arndt S et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005 162 495-506
31. Purdon SE, Jones BD, Stip E, etal. The Canadian Collaborative Group for research in schizophrenia Arch Gen Psychiatry 2000 57 249-258
32. R Development Core Team. A language and environment for statistical computing Foundation for Statistical Computing, Vienna, Austria 2008
33. Reitan RM. Validity of the trailmaking test as an indication of organic brain damage. Percept Mot Skills 1958 8 271-276
34. Rey A. Lexamen clinique en psychologie Presse Universitaire de France, Paris 1958
35. Riedel M, Muller N, Spellmann I et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007 257 402-412
36. Riedel M, Spellmann I, Strassnig M et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007 257 360-370
37. Saykin AJ, Gur RC, Gur RE et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991 48 618-624
38. Spreen O, Benton AL. Comparative studies of some psychological tests for cerebral damage. J Nerv Ment Dis 1965 140 323-333
39. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, Goldilocks actions at dopamine receptors. J Clin Psychiatry 2001 62 841-842
40. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001 62 923-924
41. Tabares-Seisdedos R, Balanza-Martinez V, Sanchez-Moreno J et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord 2008 109 286-299
42. Wiebel B, Happe A, Peikara F. Das neuropsychologische Diagnostikprogramm TESTBAT Psymed, Dulmen 1995
43. Wittorf A, Sickinger S, Wiedemann G et al. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol 2008 23 271-282
44. Woodward ND, Purdon SE, Meltzer HY et al. (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005 8 457-472